Community protocol
Third-partyNAD+ 250mg
- 01Reconstitution solution
- 2.5 mL
- 02Dose
- 25 mg
- 03Syringe units
- 25 units
- 04Frequency
- 3x/week
- 05Cycle length
- 180 days
- 06Bacteriostatic water
- 2.5 mL
- 07Bottle size
- 250 mg
- 08Bottles needed
- 8
NAD+ Precursors
Nicotinamide riboside and NMN reliably raise blood NAD+ in humans. Whether that translates into any clinical benefit remains largely unproven.
Overview
NAD+ is a coenzyme every cell needs for energy production and for the repair enzymes that maintain DNA. Its levels fall with age, and the hypothesis is that restoring them restores function. Precursors like NR and NMN do raise measured NAD+ — that part is well established in human trials. The gap is between raising the number and changing anything a person would notice. Trials measuring actual outcomes have mostly been small and mostly null on their primary endpoints.
Nicotinamide riboside is phosphorylated by nicotinamide riboside kinases to NMN, then converted to NAD+ by NMNATs. NMN itself is dephosphorylated to NR by CD73 for cellular uptake, or taken up directly via the Slc12a8 transporter reported in mouse small intestine. NAD+ is the substrate for sirtuins, PARPs and CD38, linking availability to deacetylation-dependent metabolic regulation and DNA repair. Human trials consistently demonstrate dose-dependent increases in whole-blood NAD+ of roughly 40–150%. Clinical endpoint trials in insulin sensitivity, muscle function, blood pressure and cognition have been small and largely null or equivocal; the most consistent positive signals are in surrogate markers rather than outcomes.
Research areas
NAD metabolismAgeingInsulin sensitivityMuscle function
Community-specified data
Community dosage information
Community protocol
Third-partyNAD+ 500mg
- 01Reconstitution solution
- 5 mL
- 02Dose
- 25 mg
- 03Syringe units
- 25 units
- 04Frequency
- 3x/week
- 05Cycle length
- 180 days
- 06Bacteriostatic water
- 5 mL
- 07Bottle size
- 500 mg
- 08Bottles needed
- 4
Community protocol
Third-partyNAD+ 1000mg
- 01Reconstitution solution
- 10 mL
- 02Dose
- 25 mg
- 03Syringe units
- 25 units
- 04Frequency
- 3x/week
- 05Cycle length
- 180 days
- 06Bacteriostatic water
- 10 mL
- 07Bottle size
- 1,000 mg
- 08Bottles needed
- 2
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 1000 mg nicotinamide riboside daily for 6 weeks in a randomised crossover trial in healthy middle-aged adults | Martens et al., Nature Communications 2018 |
| 250 mg NMN daily for 10 weeks in adults with prediabetes | Yoshino et al., Science 2021 |
Trial status
Numerous small randomised human trials confirming NAD+ elevation. Clinical outcome trials are small and largely inconclusive.
Reported safety signals
- Generally well tolerated in trials up to 1000 mg daily, with nausea, flushing and fatigue reported occasionally.
- Long-term safety beyond about a year is not established for either precursor.
- A theoretical concern exists that raising NAD+ could support the metabolism of existing tumours; it has not been resolved either way.
- Intravenous NAD+ infusions marketed by clinics have no controlled trial support and are not equivalent to the oral precursors that have been tested.
Common questions
If NAD+ goes up, why is the evidence still weak?
Because raising a biomarker is not the same as producing a benefit. The trials reliably show blood NAD+ rising. The trials that measured things people care about — insulin sensitivity, strength, blood pressure, cognition — have mostly been small and mostly failed to show significant improvement.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →